- Home
- NDLS vs ANTX Comparison
NDLS vs ANTX Comparison
Compare NDLS & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDLS
- ANTX
- Stock Information
- Founded
- NDLS 1995
- ANTX 2017
- Country
- NDLS United States
- ANTX United States
- Employees
- NDLS N/A
- ANTX N/A
- Industry
- NDLS Restaurants
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- NDLS Consumer Discretionary
- ANTX Health Care
- Exchange
- NDLS Nasdaq
- ANTX Nasdaq
- Market Cap
- NDLS 32.9M
- ANTX 33.2M
- IPO Year
- NDLS 2013
- ANTX 2022
- Fundamental
- Price
- NDLS $0.90
- ANTX $1.07
- Analyst Decision
- NDLS Strong Buy
- ANTX Buy
- Analyst Count
- NDLS 2
- ANTX 2
- Target Price
- NDLS $3.00
- ANTX $2.00
- AVG Volume (30 Days)
- NDLS 223.1K
- ANTX 287.9K
- Earning Date
- NDLS 08-06-2025
- ANTX 08-12-2025
- Dividend Yield
- NDLS N/A
- ANTX N/A
- EPS Growth
- NDLS N/A
- ANTX N/A
- EPS
- NDLS N/A
- ANTX N/A
- Revenue
- NDLS $495,670,000.00
- ANTX N/A
- Revenue This Year
- NDLS $5.37
- ANTX N/A
- Revenue Next Year
- NDLS $0.68
- ANTX N/A
- P/E Ratio
- NDLS N/A
- ANTX N/A
- Revenue Growth
- NDLS N/A
- ANTX N/A
- 52 Week Low
- NDLS $0.55
- ANTX $0.87
- 52 Week High
- NDLS $1.83
- ANTX $3.07
- Technical
- Relative Strength Index (RSI)
- NDLS 61.53
- ANTX 42.84
- Support Level
- NDLS $0.66
- ANTX $1.07
- Resistance Level
- NDLS $0.82
- ANTX $1.11
- Average True Range (ATR)
- NDLS 0.08
- ANTX 0.04
- MACD
- NDLS 0.02
- ANTX 0.00
- Stochastic Oscillator
- NDLS 93.68
- ANTX 7.14
About NDLS Noodles & Company
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.